Rationale for Categorizing Hydrocodone Combination Products as Schedule III

Published Online: Monday, January 20, 2014
Follow Pharmacy_Times:
In this video, Mary Lynn McPherson, PharmD, professor and vice chair at the University of Maryland School of Pharmacy, discusses why hydrocodone combination products were categorized as Schedule III in the first place.
 
This is the fifth in a series of videos in which Dr. McPherson argues in favor of categorizing hydrocodone combination products as Schedule II drugs, and Jeff Fudin, PharmD, argues against doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)
 
These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
Hae Mi Choe, PharmD, explains how metrics and tools create areas of opportunity for pharmacists.
Hae Mi Choe, PharmD, describes the challenges associated with metrics and tools for health-system pharmacy.
Hae Mi Choe, PharmD, describes how pharmacists can use metrics for reimbursement recognition.
Hae Mi Choe, PharmD, details the types of reimbursement processes available for clinical pharmacy services.
Latest Issues
$auto_registration$